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Introduction: Few studies have been done in South Africa to establish the 
extent of chronic kidney disease (CKD) in stable outpatients infected with the 
human immunodeficiency virus (HIV). Both HIV and the anteretroviral therapy 
(ART) used to treat HIV have been associated with abnormal metabolic 
profile, increased cardiovascular risk and renal disease1,2,3. Hypertension has 
been found to be common in HIV infected individuals, in European and 
American cohorts, with a prevalence ranging from 13- 34%2. Nocturnal blood 
pressure (BP) is superior to daytime or office BP as a predictor of 
cardiovascular disease4. However, the relationship between circadian BP 
patterns, measured via ambulatory blood pressure (ABP) monitoring, and HIV 
has never been documented in the South African HIV infected population. 
Individuals with an abnormal diurnal rhythm and a blunted nocturnal decline in 
systolic BP (SBP), i.e. ≤ 10%, are referred to as ‘non- dippers’ and have the 
highest risk of cardiovascular complications4. HIV itself has been associated 
with a non- dipping status and may play a role in the HIV related increase in 
cardiovascular risk5.  
 
Our aims were to: 
a) Document the prevalence of CKD at baseline in ART naive subjects, 
and document changes at 6 months on ART.  
b) Document the prevalence of hypertension at baseline in ART naive 
subjects and document changes in BP at 6 months on ART. 
c) Observe characteristics of ABP in a subset of patients at baseline and 





Subjects and Methods: We conducted a prospective cohort study of ART 
naive HIV positive patients at Crossroads Community Health Centre in Cape 
Town. Office BP and renal function parameters including: urine microalbumin: 
creatinine ratio, creatinine, urine dipsticks and estimated glomerular filatration 
rate calculation (eGFR) were measured at baseline and at 6 months, after the 
initiation of ART. A subset of patients underwent ABP monitoring. A control 
group of HIV negative patients, from Nolungile Clinic in Khayelitsha, were also 
recruited for ABP monitoring. Ethics approval was obtained from the 
University of Cape Town Research Ethics Committee (ref: 27/2006). 
 
Findings: No subject had an eGFR below 60ml/min,  3 (4.7%) patients had 
microalbuminuria and only 1 (1.6%) had overt albuminuria. No patient was 
hypertensive but there was a significant rise in office SBP after 6 months of 
ART (p- value= 0.05, 95% CI: -0.007- 0.933), this increase was not confirmed 
on ABP. 80% of HIV positive patients and 52.9% of HIV negative controls 
were non- dippers (p- value= 0.05, odds ratio = 3.56, 95% CI: 0.96- 13.13). 
The high prevalence of non- dipping on ABP monitoring was not improved by 
ART. 
 
Interpretation: The prevalence of CKD in ART naive patients in a typical HIV 
outpatient clinic is considerably lower than previously reported. This suggests 
that early introduction of ART may have a major impact on the prevalence of 






No subject was hypertensive, but non- dipping status is 3.6 times more likely 
among black HIV positive subjects than controls.  The non- dipping status was 
not improved by ART. The phenomenon is unexplained and suggests an 
underlying dyregulation of the cardiovascular system and may be associated 
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There have been 3 prospective studies performed in Africa assessing the 
prevalence of chronic kidney disease (CKD) in stable outpatients infected with 
the human immunodeficiency virus (HIV)1,2,3. No epidemiology study of this 
nature has taken place in South Africa (SA), the country housing the largest 
population of people living with HIV worldwide. Evidence of CKD at the time of 
initiation of antiretroviral therapy (ART) is an independent predictor of 
mortality in this population4. 
 
The first study was undertaken in western Kenya, which evaluated 373 
patients, renal insufficiency (i.e. Creatinine Clearance (CrCl) <60ml/min) was 
identified in 11.5% with 4.8% having a CrCl <50ml/min1. Another study was 
performed in Uganda, of 508 patients studied 20% had reduced renal function 
evidenced by a CrCl between 25 and 50ml/min. However patients with a CrCl 
of less than 25ml/min were excluded from the study so the true prevalence is 
likely to be greater than this2. A large study, of well, ART naive non-pregnant 
adults from 7 sub-Saharan African nations, investigated the prevalence of 
CKD in a cohort of 2495 patients. The prevalence of CrCl <50ml/min was low 
at 3.4%. Median CD4 count was 295 cells/ml3.  
 
CKD in HIV includes HIV associated nephropathy (HIVAN), immune complex 
diseases, thrombotic microangiopathies and vasculitidies5,6,7. In these patients 





sepsis, tuberculosis and the nephrotoxic effects of ART (e.g. tenofovir) and 
other drugs (e.g. cotrimoxazole, rifampicin)7,8,9. HIV infection has become a 
chronic and manageable disease especially where the roll- out of ART has 
been implemented for longer. With the rise of cardiovascular and metabolic 
disease in SA, hypertension and diabetes with ensuing nephropathy could 
become a greater problem in our ageing HIV infected population10.  
 
Hypertension, a major risk factor for cardiovascular disease in the general 
population, was found to be common in international studies of HIV infected 
individuals with a prevalence of up to 34%11. Nocturnal blood pressure (BP) is 
superior to daytime or office BP as a predictor of cardiovascular events and it 
is normally at least 10% lower than daytime BP (in normotensive and 
hypertensive patients)12. Individuals with an abnormal diurnal rhythm and a 
blunted nocturnal decline in systolic BP (SBP) are referred to as ‘non- 
dippers’12. These patients have the highest risk of cardiovascular 
complications and target organ disease (e.g. left ventricular hypertrophy, 
microalbuminuria)12. However, the relationship between circadian BP patterns 
and HIV has never been documented in our HIV infected population, despite 
this being the most accurate measure of risk. 
 
In studies conducted in Italy and Norway, of predominantly white HIV infected 
individuals, a high prevalence of non- dipping was found compared to equally 
matched HIV negative controls13,14. Our HIV infected population however is 
predominantly black and the incidence of non- dipping in black populations in 





The overall aim of the study will be to determine the prevalence of CKD and 
hypertension in ART naive subjects, and assess the effect of ART on CKD 
and BP. A substudy will be conducted to determine the ambulatory BP (ABP) 
characteristics of ART naive subjects compared to controls, and the effect of 




A prospective cohort study will be conducted over a period of 6 months. The 
study population will be an ambulatory HIV- infected community clinic- based 
cohort attending a community health centre in Crossroads, Cape Town. 
Crossroads has a stable population size of 41,000 with an estimated 5000 
HIV-infected individuals living in the community.  It provides services for 60- 
80 HIV infected clients daily with approximately 1500 on ART, 1200 of whom 
are adults. The yet unpublished McHAART study is an established clinical trial 
at Crossroads investigating the effects of ART on metabolic syndrome 
parameters in ART naive subjects. This study will form an important sub-
study. 
 
The following measurements will be done: urine dipstick (AccuBioTech Co. 
Ltd, Beijing, China), serum creatinine (umol/L), spot urine 
microalbumin/creatinine ratio (mg/mmol), and estimated glomerular filtration 
rate (eGFR) (ml/min/1.73m2). Measurements will be performed prior to 






Office BP will be similarly measured pre- and post 6 months of ART. A sub- 
group of patients will undergo ABP monitoring using a Spacelabs ambulatory 
BP monitor provided by the Hypertension Clinic at Groote Schuur Hospital 
(GSH). An group of confirmed serological HIV negative patients, of similar 
demographics, will be recruited from Nolungile Clinic in Khayelitsha and serve 
as a control group. 
  
Any of the subjects found to have overt nephropathy or hypertension will be 




After signing informed consent (appendix 1, 2) subjects will undergo study 
related procedures. The implications of participating in the study will be fully 
explained to all participants in IsiXhosa using fluent Xhosa speaking 
fieldworkers. 
 
Consenting patients for ABP monitoring will receive R200 to account for any 
inconvenience caused and for transport fees to and from GSH. Ethics 
approval has been obtained from the University of Cape Town Ethics 
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PART B : LITERATURE REVIEW 
 
The objectives of the literature review were to appraise published evidence 
addressing the:  
 Prevalence of HIV related renal disease in South Africa (SA)   
 Clinical application of ambulatory blood pressure (ABP) monitoring 
 Relevance of circadian blood pressure (BP) patterns 
 Relationship between circadian BP patterns and HIV 
 Effect of HIV infection and antiretroviral therapy (ART) on 
cardiovascular risk  
 
The following databases were accessed for literature; PubMed, Google 
Scholar, EbscoHost, the University of Cape Town Health Sciences Library 
and individual websites for the World Health Organisation (WHO) and South 
African Department of Health using keywords: HIV, kidney disease/ 
dysfunction, prevalence, antiretroviral therapy (ART)/ highly active 
antiretroviral therapy (HAART), ambulatory blood pressure monitoring, blood 
pressure, hypertension, diurnal variation and South Africa. The years 1985- 
2012 were searched and 39 articles were identified. 36 articles contained 
relevant information, namely: 11 on the prevalence and impact of renal 
disease in HIV positive individuals1-11, 7 on measuring ambulatory BP and its 
clinical relevance12-18 and 18 on the effect of HIV on circadian BP patterns 
and the metabolic consequences of HIV and ART19-36. Due to the paucity of 
data available all pertinent clinical research publication types (i.e. systemic 





There have been very few prospective studies on the prevalence of chronic 
kidney disease (CKD) in HIV positive patients in sub-Saharan Africa. The 
prevalence of CKD was estimated at: 2.4% in Rwanda1, 11.5% in Kenya2, 
20% in Uganda3, 25% in Tanzania4, 33.5% in Zambia5 and 3.4% in a large 
cohort from 7 sub-Saharan nations6. These studies (as described below) had 
different methods for defining CKD and the patients enrolled had various 
WHO clinical stages of HIV, which may account for the large discrepancies in 
prevalence.  
 
In a cross- sectional study in western Kenya of the 373 patients enrolled 
11.5% had CKD (creatinine clearance (CrCl) <60ml/min) and 4.8% of these 
patients had CrCl <50ml/min. Thus, in this medically stable cohort, CKD was 
not uncommon. Proteinuria (defined as ≥1+ protein on dipstick) was present in 
6.2 % of patients2. This prevalence of proteinuria is similar to other African 
studies (Rwanda1, SA7, Uganda3) ranging between 6% and 9% of patients 
studied.  
 
In a descriptive single centre study in Johannesburg, SA the prevalence of 
proteinuria (including microalbuminuria) was high in 253 (43.7%) of the 576 
HIV positive patients that were screened. This study cohort was 
predominantly black (n=560, 97%). The aim of this study was to detect early 
kidney disease by screening for proteinuria but additional abnormalities, 
including leucocyturia 30.3% (n= 175) and microscopic haematuria 33.1% (n= 
191), were found. Although this study suggests a high prevalence of 





mentioned above, 482 of the 576 patients (84%) were classified as having 
AIDS (CD4 count <200 cells/mm3). Also, in the group with microalbuminuria 
(n=107, 18.5%) the prevalence of co-morbid disease (tuberculosis, 
cardiovascular disease, infection, diabetes, malignancy) was high. This study 
concluded that urinary abnormalities in HIV infected, ART naive patients are 
common thus recommends routine urinary screening in HIV clinics. No follow 
up was done in this study to determine whether resolution or reversal of 
urinary screening abnormalities occurred with appropriate treatment8.  
 
A randomised controlled trial in Uganda followed a HIV positive cohort (n= 
508) after initiation of ART. Most of the patients had advanced HIV disease 
(median CD4 cell count 122 cells per mm3, median HIV viral load of 244500 
copies per ml). The baseline prevalence of CKD was 20% with CrCl between 
25 and 50ml/min. Patients with CrCl less than 25ml/ min were excluded 
meaning that the true prevalence of CKD was probably greater than this. 
Following 2 years of ART they also found that renal function improved with the 
serum creatinine decreasing by 16% (p< 0.0001) and CrCl significantly 
improving by 21% (p< 0.0001)3. 
 
A study using data from a mother- to- child transmission network investigated 
the prevalence of CKD in well (median CD4 count 295 cells/ml), HIV- infected, 
ART naïve non- pregnant adults from 7 sub- Saharan nations. Of the 
predominantly female cohort of 2495 the overall prevalence of CrCl< 50 






In a 3 year multicentre cohort study conducted in Lusaka, Zambia 36239 
treatment naive HIV positive adults were recruited. They found 8456 (33.5%, 
95% CI: 32.9-34.1%) of the 25779 eligible for statistical analysis had CKD. 
The researchers used published clinical guidelines from the U.S. National 
Kidney Foundation's Kidney Disease Outcome Quality Initiative (K/DOQI) to 
categorize renal insufficiency. Of the 8456, 73.5% had stage 2 CKD, 23.4% 
had stage 3 CKD and 3.1% had stage 4 CKD. The predictors of renal 
dysfunction in this study included: female sex, BMI<18.5 kg/m2, haemoglobin 
<8g/dL and WHO HIV stage 3 or 45. Microalbuminuria was found in 70% of 
patients which is also associated with mortality in HIV infected women1. 
Advanced HIV stage was also associated with decreased renal function in the 
studies conducted in Western Kenya2 and Nigeria9 but this was not the case 
in the Rwanda study1.  
 
An observational prospective study, comparing HIV positive and HIV negative 
Rwandan women, enrolled 936 participants. Of this group 710 were HIV 
positive and 226 HIV negative. The median CD4 count in these women was 
256 and 41.5% were classified as having WHO stage 4 HIV. The prevalence 
of CKD was low with 2.4% (n= 21) having an estimated glomerular filtration 
rate (eGFR) <60ml/min/1.73m2 calculated by the 4- variable Modification of 
Diet in Renal Disease (MDRD) equation. Proteinuria was present in 9% (n= 
64) of the patients which was not associated with HIV status (adjusted odds 
ratio (OR) 1.7, 95% CI: 0.7- 4.1). However, HIV infection was independently 
associated with decreased eGFR (adjusted OR 8.9, 95% CI: 1.6- 50.5) after 





Some studies in sub-Saharan Africa assessed the prevalence of kidney 
disease by renal biopsies. These were done in SA (Cape Town10, 
Johannesburg11, Durban7) and in Nigeria9. These studies show a wide 
spectrum of histopathological lesions in HIV infected individuals but HIV-
associated nephropathy (HIVAN) was the most common biopsy finding7,9,10,11. 
Additional lesions found were: immune complex disease10,11,  other 
glomerulonephritidies7,10,11 and thrombotic microangiopathies7,10. 
 
Hypertension is a common in the adult population of SA and is a major cause 
of morbidity and mortality. Office BP is an important tool to diagnose 
hypertension, but has limited value for both diagnosis and prediction of 
cardiovascular outcome.  ABP monitoring, on the other hand, enhances the 
ability to identify white coat hypertension and the masked effect as well as 
eliminating bias introduced by inaccuracy and human error12. ABP is also 
more closely associated with cardiovascular complications12. This has been 
confirmed in the SA population even in patients with normal or mildly raised 
BP13. ABP is better than office BP in assessing circadian rhythm and BP 
variability12. The normal circadian pattern is where the night-time systolic BP 
(SBP) falls by ≥10% and increases on waking14,15. Individuals with a nocturnal 
SBP fall less than 10%, referred to as ‘non- dippers’, have an increased risk of 
cardiovascular complications13-17. A non- dipping BP pattern is also 







Two studies have evaluated 24-hour ABP in HIV positive patients19,20. The 
prevalence of non-dipping BP pattern, in a Norwegian study of 77 
hypertensive HIV positive individuals, was high and significantly more than in 
76 hypertensive controls (59.7% vs. 32.9%, p=0.001). Non- dipping was 
independently associated with HIV status (OR 0.33, 95% CI: 0.17-0.66, 
p=0.002), but not microalbuminuria (OR 1.001, 95% CI: 0.99-1.04, p=0.37) or 
office SBP (OR 1.56; 95% CI: 0.57-4.28, p=0.39). There were no statistically 
significant difference in office or ABP between ART naïve (n= 13) and ART 
treated subjects (n=64)19.  
 
An Italian study assessed ABP in ART naive HIV infected individuals (n= 52) 
and in healthy HIV negative control subjects (n= 156). The controls were 
accurately matched by: age, BP, sex and Framingham risk score. The 
prevalence of non- dipping was found to be 35% in the HIV positive group and 
15% in the control group (p=0.003). The night-time SBP and diastolic BP 
(DBP) was significantly greater in the HIV positive individuals than the 
controls (113/69 ± 11/9mmHg vs. 109/67 ± 8/6mmHg, p=0.008 vs. 0.005). 
The mean nocturnal SBP fall was 8.8% in the HIV positive cohort and 11.7% 
in the control group. The independent contribution of HIV infection and other 
variables (sex, office SBP, age, sex, smoking status) to nocturnal BP 
reduction was tested in a stepwise multiple linear regression analysis. HIV 
infection was the only independent determinant of nocturnal SBP fall. These 






As noted above the only published data on the effect of HIV on circadian BP 
patterns are from Norway and Italy. These studies involve white patients from 
developed countries. Our HIV infected population is predominantly black and 
younger. In addition to this HIV negative African Americans, both 
normotensive and hypertensive subjects, exhibit more non- dipping during 
ABP monitoring than do whites21. A SA study, comparing ABP in black and 
Indian medical students, revealed less nocturnal dipping and a higher left 
ventricular mass (identified by echocardiography criteria) in young black 
participants than young Indians13. A nocturnal non- dipping pattern has been 
linked to: high dietary sodium intake, lower dietary potassium intake, salt 
sensitivity, sleep apnoea, obesity, lower socio-economic status and CKD in 
blacks21,22. The contribution of HIV to nocturnal non- dipping status has not to 
date been assessed in the SA population.  
 
In addition, HIV infection and the use of ART have been associated with an 
increase in: insulin resistance, dyslipidaemia and lipodystrophy23,24. In HIV 
infected individuals chronic infection promotes chronic arterial inflammation 
and injury and in turn causes endothelial dysfunction, hypertension 
accelerated atherosclerosis and a higher risk of acute myocardial 
infarction25,26. 
 
The effect of ART on BP has shown contrasting results in the literature. ART 
was shown to increase BP in 6 studies24,27-32. Further, the duration of therapy 
was associated with a greater risk of hypertension27,32. 3 studies found that 





conducted for only 6 months and a longer period of observation would be 
required to determine causation35. 
 
As illustrated the available literature suggests that CKD and proteinuria in 
medically well, HIV positive outpatients is highly varied.  More research is 
needed to determine the risk of CKD in well HIV positive patients and the cost 
effectiveness of regularly screening these patients. 
 
Our literature review revealed important implications for the design of the 
MMed research proposal. For comparison purposes with the available 
literature, on kidney disease in HIV, we decided to measure similar renal 
function parameters as used in these publications. It included: urine dispticks, 
creatinine, microalbuminuria and eGFR as calculated by the 4- variable 
MDRD formula36. Although the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation has shown improved performance, 
compared to the MDRD, at higher levels of eGFR it has not been validated 
amoung Africans37. GFR categories in CKD were assigned according to the 
latest clinical guidelines from the Kidney Disease: Improving Global Outcomes 
(KDIGO) group38. Although albuminuria categories in CKD have also been re-
classified, in these guidelines, the terms ‘microalbuminuria’ and 
‘macroalbuminuria’ are still predominantly used in the literature. A urinary 
albumin/creatinine ratio between 3-30 mg/mmol would be identified as 
microalbuminuria and a level greater than this as macroalbuminuria39. Due to 
the apparent beneficial effects of ART on renal function we planned to 





As most of our patients would be black and of a low socio-economic status, 
the need for a HIV negative control group of a similar racial and demographic 
profile for the ABP substudy was deemed necessary. This would eliminate the 
possible overestimation of non- dipping status in our black study population. 
 
The literature on the development and clinical application of ABP informed our 
decision on how to measure and classify dipping status.  It was decided to 
measure BP on a typical weekday when daytime activity and duration of night-
time bed rest could be more accurately reproduced14. The process of BP 
dipping is not likely to occur when a person does not sleep at night, as 
exemplified by night shift workers18,40. To define night time we adopted the 
commonly used period from 22h00- 06h0018,40.  
 
Known conditions associated with non- dipping include: endocrine conditions 
such a hyperthyroidism, renal dysfunction, and disturbances of the autonomic 
system (i.e. diabetic neuropathy, obstructive sleep apnoea) and other 
influences (i.e. malignant hypertension, pre- eclamptic toxaemia)18. In order to 
determine the intrinsic effect of HIV on circadian BP trends we decided to 
include only well, ambulant outpatients in our study.  
 
On review of the evidence it is clear that the exact mechanism explaining the 
apparent association between HIV infection and an impairment of nocturnal 
BP fall is yet to be fully determined. Also, guidelines and protocols regarding 
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Objectives: HIV and antiretroviral therapy are associated with renal disease 
and increased cardiovascular risk. The relationship between HIV and 
ambulatory blood pressure (ABP) dipping status, a risk factor for 
cardiovascular events and target organ damage, has never been assessed in 
South Africa. Study objectives were to: establish the prevalence of chronic 
kidney disease and assess the ABP profile in well HIV positive outpatients.  
Methods: This was a prospective cohort study of healthy HIV positive clinic 
outpatients. Office blood pressure (BP), urinary microalbumin/creatinine 
ratio, urine dipsticks, serum creatinine and estimated glomerular filtration rate 
(eGFR) were measured at baseline and 6 months after antiretroviral therapy 
initiation. A subset of HIV positive subjects, and HIV negative control group, 
underwent 24 hour ABP monitoring.   
Results: No patient had an eGFR<60ml/min,  3 patients (4.7%) had 
microalbuminuria and 1 (1.6%) had macroalbuminuria. Mean office systolic 
BP was 111 ± 14 mmHg at baseline and increased by 5 mmHg to 116 ± 14 
mmHg (p= 0.05) at 6 months. This increase was not confirmed by ABP 
monitoring. In the HIV positive and negative patients the prevalence of non- 
dipping was 80% and 52.9% respectively (p- value= 0.05, odds ratio = 3.56, 
95%, CI: 0.96 - 13.13). No relationship between dipping status and 
antiretroviral usage was found.   
Conclusion: The prevalence of chronic kidney disease (CKD) was lower than 
anticipated. HIV infection was associated with an ambulatory non-dipping 





system. Antiretroviral therapy does not seem to improve circadian rhythm 
loss.   
Key words: Human immunodeficiency virus, antiretroviral therapy, 





This is a prospective study of well HIV positive outpatients, and HIV negative 
controls. Office blood pressure (BP), chronic kidney disease (CKD) markers 
and ambulatory BP (in a subset of patients) were measured at baseline and 6 
months after the initiation of antiretroviral therapy (ART). The CKD prevalence 
was lower than anticipated. HIV infection was associated with a high 
prevalence of ambulatory non-dipping status, which suggests an underlying 
dysregulation of the cardiovascular system. The pathophysiology of this 
phenomenon, which contributes to cardiovascular risk in HIV positive patients, 
remains unexplained. ART does not seem to improve the loss of circadian 














South Africa has 5.6 million people living with HIV/AIDS and has the largest 
antiretroviral therapy (ART) program globally with more than 2 million people 
accessing ART [1]. Although ART has significantly decreased the mortality 
from HIV infection, these individuals are now living longer and are at risk of 
developing metabolic (dyslipidaemia, lipodystrophy, dysglycemia), 
cardiovascular and renal complications from ART and chronic exposure to 
HIV infection [2-7]. Chronic HIV and ART are associated with increased risk of 
developing hypertension [8]. In studies of HIV positive patients in high income 
countries, hypertension prevalence ranges from 13- 34% [9,10]. However, 
data from low and middle income countries remains sparse.   
 
Nocturnal blood pressure (BP) is superior to daytime or office BP as a 
predictor of cardiovascular disease [11]. Non- dipping is defined as an 
abnormal  diurnal rhythm manifested by a blunted nocturnal decline in systolic 
BP (SBP) [11]. It is associated with more severe hypertensive target organ 
damage (left ventricular hypertrophy, microalbuminuria and cerebrovascular 
disease) and is also a predictor of increased cardiovascular risk, both in 
hypertensive and normotensive populations [11]. Studies from high-income 
countries have shown an  increased prevalence of non- dipping with HIV 
infection [9,12]. However, the participants in these studies were largely white, 
middle-aged, males.  Since the majority of subjects with HIV infection in sub-
Saharan Africa are young black females it is not known whether  the same 





addition, there is data showing that black HIV negative individuals have less 
nocturnal dipping compared to their white counterparts [5,13,14].   
 
Therefore, the aims of the present study were to document the prevalence of 
chronic kidney disease (CKD) and hypertension at baseline (ART-naive), in a 
healthy HIV positive cohort, and to assess changes in these parameters after 
6 months on ART.  The characteristics of ambulatory blood pressure (ABP) in 
a subset of patients were to be recorded and compared to a control group of 




A longitudinal, prospective cohort study was conducted. The study was 
approved by the Research Ethics Committee of the Faculty of Health 
Sciences of the University of Cape Town. Before participating in the study, 
procedures and risks were explained to the patients, who gave written 
informed consent to participate in the study. This study formed part of a yet 
unpublished larger longitudinal study, investigating the metabolic 
complications of ART in a HIV- positive population, at a HIV clinic in a 
community health center in Cape Town, South Africa. 
 
All patients recruited for the parent study, over a 6 month period, were 
enrolled into the present study. The following measurements were done at 
baseline and repeated at 6 months: urine dipstick (AccuBioTech Co. Ltd, 





microalbumin/creatinine ratio (mg/mmol), and estimated glomerular filtration 
rate (eGFR) (ml/min/1.73m2). Three office BP readings were performed on the 
right arm with the patient in a seated position using a mercury barometer in 
accordance with the South African hypertension guidelines [15]. A urinary 
albumin/creatinine ratio between 3-30 mg/mmol was identified as 
microalbuminuria and a level greater than this as macroalbuminuria [16]. 
eGFR was estimated using the 4-variable Modification of Diet in Renal 
Disease (MDRD) equation which accounts for the sex, age, creatinine and 
race of a patient [17]. Clinical guidelines from the Kidney Disease: Improving 
Global Outcomes (KDIGO) work group were used to categorize CKD [18]. 
 
After the baseline measurements all patients were commenced on ART 
(Table 1). The treatment regimen used depended on the date of enrolment 
into the study. Initially patients were prescribed stavudine (D4T), lamivudine 
(3TC) and efavirenz (EFV) according to the previous National Guidelines, but 
later tenofovir (TDF) replaced D4T [19,20].  
  
All enrolled patients were invited to participate in the ABP sub-study. 
Consenting individuals underwent ABP monitoring prior to and after the 
initiation of ART.  A control group of confirmed serological HIV negative 
patients formed a control group of another study from our institution 
investigating HIV associated dementia [21]. They were originally recruited by 
trained fieldworkers from a community primary healthcare clinic in Cape 
Town. Seventeen individuals, from of a list of 32 contacted telephonically, 





index (BMI) and socioeconomic background. Patients were excluded if they 
had underlying hypertension, diabetes mellitus, ischaemic heart disease, 
concurrent illness or any condition affecting BP (i.e. pregnancy or renal 
disease).  
 
ABP monitoring was set up by a trained nurse, on a weekday with an 
oscillometric device (SpaceLabs Medical Inc, WA, USA). BP and heart rate 
were recorded every 20 minutes during the day (06h00- 22h00) and every 30 
minutes at night (22h00- 06h00). Hypertension was defined as a SBP ≥140 
mmHg or diastolic BP (DBP) ≥90 mmHg, in accordance with the South African 
Hypertension Guidelines 2011 [15]. Non- dipping was defined as a nocturnal 
reduction of SBP≤ 10% [22].  
 
Statistical analyses were performed using STATA statistical software, version 
11.0 (STATA Corporation, College Station, Texas, USA). Mean ± standard 
deviation was used for normally distributed data and median plus interquartile 
ranges for skewed data. Continuous and categorical variables were compared 
using chi2, student t-test or Pearson’s X2 as appropriate. All P-values 




Sixty four patients were entered into the study with baseline characteristics as 







Table 1: Patient characteristics and demographics  
 
 Baseline  
(n= 64) 










Age (years) mean ±SD 
Men (%) 
Women (%) 
BMI (kg/m2) mean ±SD 
 Men 
 Women 
CD4 (cells/mm3) median  
(IQR) 
ART regimen (%) 




33 ± 7 
23 
77 
24.8 ± 5.4 
22.5 ± 4.6 










33 ± 7 
23 
77 
25.7 ± 5.2 
23.1 ± 4.8 







32 ± 8 
37 
63 
24.6 ± 5.2 
22.9 ± 5.0 







32 ± 8 
36 
64 
24.8 ± 5.4 
22.7 ± 5.3 
25.8 ± 5.4 
361 





31 ± 9 
40 
60 
24.0 ± 4.8 
22.8 ± 5.1  







All were black South Africans, mean age 33 years ± 7, and 77% were female. 
Eleven patients were excluded on follow up [defaulted treatment (n=8), 
pregnancy (n=3)]. Mean BMI was 24.8 kg/m2 ± 5.4 and increased to 25.7 
kg/m2 ± 5.2 after 6 months on ART (p= 0.39). At baseline median CD4 count 
was 239 (169- 322) cells/mm3, and after 6 months of ART the CD4 count 
increased to 359 (231- 411) cells/mm3. All patients had suppressed viral 
loads. Thirty two patients agreed to participate in the ABP substudy (2 were 





those who underwent ABP monitoring and those who did not according to 
age, gender, ethnicity, BMI, CD4 count, ART status or office BP. Baseline 
demographics were similar in the HIV negative control group except there 
were more males in this group compared with the HIV positive cohort. 
However, there were still a greater percentage of females than males in the 
control group (Table 1).   
 
At baseline, 13 patients (20%) had an eGFR 60- 89 ml/min/1.73m2 (GFR 
category G2). No patient had an eGFR <60ml/min/1.73m2 (Table 2). 
Microalbuminuria was present in 3 of the 64 patients (4.7%) and only 1 patient 
(1.6%) had macroalbuminuria. At the end of 6 months, microalbuminuria 
persisted in the 3 patients and developed in 2 new cases. The patient who 
initially had macroalbuminuria resolved on follow-up sampling. No patient had 
a change in eGFR over the study period. 
TABLE 2: BP and Renal parameters at baseline and 6 months 
 Baseline 
(n= 64) 
6 Months  
(n=53) 
p- value 
MDRD eGFR (ml/min/1.73m2) 
 
≥ 90, n (%) 
 
60-89, n (%) 
 
< 60, n (%) 
 





















Microalbuminuria (mg) 0.9 +/- 5.0 0.8 +/- 2.8 0.67 
Office Systolic BP [SBP] (mmHg) 111+/- 14 116 +/- 14 0.05 







Mean office SBP increased significantly from 111 ± 14 mmHg at baseline to 
116 ± 14 mmHg (p= 0.05) at 6 months, but this was not confirmed by the ABP 
substudy (Table 2). The mean day and night ABP values for each group are 
shown in table 3. The mean nocturnal SBP was higher at 110 ± 6 mmHg in 
the HIV positive group at baseline compared to 99 ± 6 mmHg in the control 
group (p< 0.0001). There were no significant differences in  age, gender, 
ethnicity, BMI, CD4 count, ART status or office BP between patients who did 
or not undego ABP monitoring. The prevalence of non-dipping in HIV positive 
patients (Table 3), did not differ at baseline  or after  6 months on ART.  
Twenty four of 30 subjects (80%) were non-dippers at baseline and 23 of 28 
subjects (82%) (odds ratio= 1.15, p= 0.84, 95% CI: 0.31- 4.29) were non- 
dippers at 6 months.  In the HIV negative control group 9 of 17 (52.9%) were 
non- dippers, thus  non- dipping was 3.6 times more likely in HIV positive 
patients at baseline than controls (p= 0.05, 95% CI: 0.96 - 13.13).  
TABLE 3: Mean day and night BP and dipping status in 30 patients with HIV and in 17 
control subjects. 
 HIV positive HIV negative Baseline BP 
vs. controls 
(p- value) 
Baseline 6 months 






114 +/- 10 
75 +/- 12 
110 +/- 6 
65 +/- 8 
 
116 +/- 12 
72 +/- 11 
111 +/- 4 
67 +/- 11 
 
114 +/- 14 
73 +/- 16 
99 +/- 6 






Non-dipper 24 (80%) 23 (82%) 9 (52.9%) - 
Dipper 6 (20%) 5 (18%) 8 (47.1%) 0.05 







This is the first study from Africa, to our knowledge, to have used ABP 
monitoring to characterize differences in nocturnal blood pressure dipping 
status between HIV-positive and HIV-negative patients.  The study found that: 
(1) there is a low prevalence of CKD and microalbuminuria in healthy HIV-
positive patients; (2) there is a greater prevalence of non-dipping of nocturnal 
blood pressure in HIV-positive patients than HIV-negative controls.  
  
Studies from a high income country found the estimated prevalence of CKD in 
HIV infected subjects to be 11 to 15.5% [23, 24]. Our study found a lower 
prevalence of microalbuminuria in HIV-positive patients.  In contrast, a study 
from Johannesburg  reported a  prevalence of microalbuminuria of 18.5% in 
their cohort of HIV-positive patients [25]. A possible explanation for this 
difference is that their patients were significantly more immunosuppressed 
(CD4 < 200 cells/mm3) with a mean CD4 count of 130 cells/mm3. They also 
had a high prevalence of co-morbid disease whereas the patients in our study 
were all healthy, with a mean CD4 count of 239- 339 cells/mm3. 
 
Microalbuminuria is an important finding in HIV as it may reflect early kidney 
disease. In a study from Kwazulu-Natal, 6 of 25 (24%) patients with an eGFR 
>60 ml/min/1.73m2 had persistent microalbuminuria and HIV-associated 
nephropathy (HIVAN) detected on renal biopsy [26]. This is an isolated study. 
It is important to note that renal biopsies are not routinely performed in 





series from Cape Town, HIVAN presented with nephrotic range proteinuria 
and impaired renal function [7]. Patients not receiving ART had a poor 
prognosis [27,28]. Microalbuminuria is non specific and is a marker of 
inflammation and cardiovascular risk independent of renal function [29]. 
 
In this small study, no patient had a clinically relevant reduction in eGFR (<60 
ml/min/1.73m2), and only 1 patient had overt macroalbuminuria (which 
resolved on treatment with ART). This suggests that the approximate 
prevalence of CKD in an otherwise healthy HIV population is about 1.6%, 
considerably lower than previously reported [23, 30]. Importantly a high CD4 
count and normal creatinine does not exclude renal disease in HIV [6, 7, 26]. 
Patients demonstrating proteinuria, who would not normally be eligible for 
ART due to an elevated CD4 count, benefit from timely initiation of ART which 
can greatly improve survival with stabilisation of eGFR [7,30]. Therefore 
screening of patients enrolling into an ART program, with urine dipsticks or 
spot urine sampling for proteinuria, should be standard practice and could 
have an impact on the prevalence of HIVAN. This is particularly important in 
SA where, due to the problem of limited access to renal replacement, there is 
a need for early identification and management of renal disease. 
 
In this study no cases of hypertension were identified, and there was a small 
but significant increase in office SBP after 6 months on ART. However in a 
subset of patients ABP monitoring did not confirm these findings. ABP 
monitoring is the most reliable method of assessing BP and suggests that 





In the ABP substudy there was no difference in mean day time SBP and DBP 
between patients and controls. However the mean night time SBP was 
significantly higher in the HIV group as was the proportion of non- dippers 
compared to the control group with similar demographics (BMI, age, sex, 
socioeconomic status). A non- dipping pattern is an established entity with 
important clinical implications, and is associated with a higher cardiovascular 
morbidity and mortality [31]. The high prevalence of non- dippers in the HIV 
infected group, in this study, supports the data from Italy and Norway [9,12]. 
 
The potential mechanisms underlying the non- dipping phenomenon in HIV 
positive patients are uncertain. It does suggest an underlying dysregulation of 
the cardiovascular system. Chronic infection and arterial inflammation 
contribute to endothelial dysfunction which may be further exacerbated by 
ART [2,3]. In addition, HIV related endocrinopathies (i.e. hyperaldosteronism 
and hypercortisolism) and autonomic dysfunction may play a role [32,33]. 
However the lack of improvement in dipping status after 6 months of ART with 
suppressed viral loads suggests that other mechanisms may also be involved. 
 
Our study has several limitations. Firstly, the sample size for the ABP 
substudy is small and the nocturnal dipping status between HIV positive and 
negative controls is marginal.  Secondly, the short length of follow up (6 
months) may be a limitation as the effects of ART on BP and nocturnal 
dipping may take longer to manifest.  Thirdly, a single spot sample was used 
for establishing microalbuminuria. Lastly, ABP measurements were conducted 





daytime activity and duration of night time bed rest which has been shown to 
affect diurnal BP patterns. 
 
The focus of HIV care, in our country, remains virological suppression and 
managing opportunistic infections. Our findings correlate with established 
evidence linking HIV to increased cardiovascular risk. Young black females 
are traditionally at low risk for cardiovascular disease. However a non- dipping 
status, in the context of HIV infection, could confer a greater risk in this group. 
If there are approximately 5.6 million HIV positive people in South Africa 
potentially 4.48 million (80%) are non- dippers. Therefore, as HIV infected 
patients are living longer, investigating and addressing the cardiac and 
metabolic complications related to HIV is becoming more important.  
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Patient information sheet and consent form:  
Ambulatory blood pressure study 
 
You are invited to participate in a research project conducted by the Nephrology 
Department at Groote Schuur Hospital.  
 
Patients will be referred to the high blood pressure clinic at Groote Schuur 
Hospital (E17) to undergo ambulatory blood pressure monitoring. This is a 24 hour 
blood pressure monitor that is applied to your upper arm. It must stay on for the 
whole day and night. There are no risks to your health by wearing the monitor and it 
is painless. It may inconvenience you, especially at night, as the machine needs to 
blow up and down approximately every 20 minutes. However, it will give us useful 
information about your blood pressure throughout the day and night. If you are found 
to have high blood pressure we can arrange further treatment for you. 
 
We will pay you R200 for participating in the study and to cover transport costs to 
and from Groote Schuur hospital. Two trips to Groote Schuur hospital will be required 
to fit the machine and then to return it. 
 
You do not have to participate in this study. Your participation is voluntary and if 
you agree to participate you will be required to sign this form. You can withdraw from 
this study at any time (provided blood pressure monitors are returned to Groote 
Schuur hospital) and this will not affect your future treatment. 
 
Your details will not be viewed by anybody not involved in this study and we will 
strive to keep your records confidential.  
 
 
Should you have any questions please contact Dr Borkum on 0722465633. 
 
 




____________      _____________ 
Patient print name      Patient signature 
 
 




____________      _____________  









Patient information sheet and consent form:  
Prevalence of kidney disease study 
 
You are invited to participate in a research project conducted by the Nephrology 
Department at Groote Schuur Hospital.  
 
Patients will be required to have blood taken and to give a urine sample at 
Crossroads clinic. We will also test your blood pressure. There are no risks to your 
health by participating. However, these tests will give us useful information about 
your kidney function and blood pressure. If you are found to have high blood 
pressure or kidney problems we will inform you and can arrange further treatment for 
you. 
 
In 6 months, after starting antiretroviral treatment, we will repeat the blood and urine 
tests if you agree. 
 
You do not have to participate in this study. Your participation is voluntary and if 
you agree to participate you will be required to sign this form. You can withdraw from 
this study at any time (provided blood pressure monitors are returned to Groote 
Schuur hospital) and this will not affect your future treatment. 
 
Your details will not be viewed by anybody not involved in this study and we will 
strive to keep your records confidential.  
 
 
Should you have any questions please contact Dr Borkum on 0722465633. 
 
 




____________      _____________ 
Patient print name      Patient signature 
 
 




____________      _____________  
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